BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $14.96B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 2.81M
Average 2.49M
BBIO EBITDA Margin
EBITDA as a percentage of revenue.
BridgeBio Pharma, Inc.NASDAQ: BBIO
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to -58.1%
EBITDA Margin was -58.1% in Q2 FY2026, up 71.0 pp from a year earlier. On a trailing-twelve-month basis it was -85.7%, up 187.2 pp year over year. Over 3 fiscal years it widened by 377.1 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 13 analysts of -32.7% for the fiscal year ending Dec 2026, up from -134.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -58.1%-0.2 pp QoQ
- Last fiscal yearDec 2025
- -134.7%+62.1 pp YoY
- LTMJun 2026
- -85.7%+187.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -134.7%
- Year-over-year change
- +62.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -134.7% | +62.1pp |
| FY2024 | 2024-12-31 | -196.9% | +5881.5pp |
| FY2023 | 2023-12-31 | -6078.3% | -5566.5pp |
| FY2022 | 2022-12-31 | -511.9% | +253.9pp |
| FY2021 | 2021-12-31 | -765.7% | — |
EBITDA Margin vs competitors
How BBIO compares with its peers on the latest reported figures
- BBIO's LTM Jun 2026 EBITDA Margin of -85.7% is the 8th highest of the 11 companies compared; the peer median is -32.9%.
- Its year-over-year change of +187.2 pp is the highest of 9, against a peer median of -20.8 pp.
- Over three fiscal years its change of +377.1 pp compares with a peer median of +105.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 24.0% | +30.9 pp | +106.3 pp | |
| LTM Sep 2026 | 21.5% | +42.1 pp | +1018.2 pp | |
| LTM Jun 2026 | 17.2% | -30.5 pp | +103.9 pp | |
| LTM Sep 2026 | -8.0% | -32.9 pp | +5.1 pp | |
| LTM Sep 2026 | -16.4% | -11.2 pp | +278.1 pp | |
| LTM Sep 2026 | -49.3% | -33.5 pp | +8.7 pp | |
| LTM Mar 2026 | -75.2% | +1.0 pp | +105.9 pp | |
| LTM Jun 2026 | -85.7% | +187.2 pp | +377.1 pp | |
| LTM Mar 2026 | -597.6% | -631.1 pp | — | |
| LTM Jun 2026 | -13823.7% | — | — | |
| LTM Sep 2026 | -69878.4% | — | — | |
| Peer median (excluding BBIO) | -32.9% | -20.8 pp | +105.9 pp | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M |
| Cost of Revenue | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M |
| Gross Profit | 66.6M | 74.21M | 6.86M | 218.02M | 473.81M |
| Gross Margin | 95.5% | 95.6% | 73.7% | 98.3% | 94.4% |
| Research & Development | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M |
| Selling, General & Admin | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M |
| Operating Expenses | 643.23M | 586.42M | 614.23M | 811M | 1.04B |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| EBITDA | (533.83M) | (397.44M) | (565.47M) | (436.83M) | (676.45M) |
| EBITDA Margin | -765.7% | -511.9% | -6078.3% | -196.9% | -134.7% |
| Operating Income | (576.63M) | (512.2M) | (607.37M) | (592.97M) | (569.09M) |
| Operating Margin | -827.1% | -659.6% | -6528.8% | -267.2% | -113.3% |
| Interest Income | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M |
| Interest Expense | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M |
| Other Income / Expenses | (9.82M) | 27.55M | (45.88M) | 50.78M | (165.9M) |
| Income Before Tax | (586.45M) | (484.65M) | (653.25M) | (542.19M) | (734.99M) |
| Pre-Tax Margin | -841.2% | -624.2% | -7021.9% | -244.3% | -146.4% |
| Income Tax Expense | 0 | 0 | 0 | 1.15M | 555K |
| Net Income | (562.54M) | (481.18M) | (643.2M) | (535.76M) | (729.31M) |
| Net Margin | -806.9% | -619.7% | -6913.9% | -241.4% | -145.3% |
| EPS (Basic) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| EPS (Diluted) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| Weighted Avg Shares | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
| Weighted Avg Shares (Diluted) | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$76.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.